Laurus Labs financials

·Pharma & HealthChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹2,206cr+33.4% on Q2 FY26
Net profit
₹436cr+124.3% on Q2 FY26
EBITDA margin
34.0%+9.6 pts on Q2 FY26
EPS
₹8.17+126.3% on Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue2,2061,653+33.4%
EBITDA750403+86.1%
EBITDA margin34.0%24.4%+9.6 pts
Profit before tax592270+119.4%
Net profit436194+124.3%
EPS₹8.17₹3.61+126.3%

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹2,206 crNet profit₹436 crNet margin19.8%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1,17,790————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
24.511399.513945.7
1201311304.611.1
2,3972,3972,6932,5071,972
1,20,283————
7,8236,8135,5545,0416,041
—+22.7%+10.2%−16.6%—
2,3811,7781,0557781,592
30.4%26.1%19.0%15.4%26.4%
1,8871,2986253931,268
1,332890358162793
17.0%13.1%6.5%3.2%13.1%
₹24.82₹16.46₹6.64₹2.97₹14.64
—+148.0%+123.2%−79.7%—
—1,624602666994
—−1,070−641−678−990
554554−39.4−12.63.7
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LAURUSLABS₹2,181.90

Laurus Labs Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABGLANDMANKINDBIOCONALKEMLUPINFORTISGLENMARKMcap ₹1.18L Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————1,17,789.9
- Cash, Equiv & ST Investments45.7138.999.5112.724.5
+ Minority Interest11.14.6130.0131.3120.5
+ Total Debt1,972.02,507.12,693.12,397.52,397.5
Enterprise Value————1,20,283.4
Revenue6,040.65,040.85,554.06,812.97,822.5
Growth %, YoY—-16.6+10.2+22.7—
EBITDA1,592.2777.51,055.31,777.72,380.9
Margin %26.3615.4219.0026.0930.44
EBIT1,268.1392.9625.21,297.71,886.9
Net Income793.4162.3358.3890.11,332.2
Margin %13.143.226.4513.0717.03
EPS, Adj (current shares)14.642.976.6416.4624.82
Growth %, YoY—-79.7+123.2+148.0—
Cash from Operations993.9665.7601.71,623.5—
Capital Expenditures-990.2-678.3-641.0-1,070.0—
Free Cash Flow3.7-12.6-39.4553.6553.6
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Laurus Labs financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Laurus Labs (NSE: LAURUSLABS) had a market capitalisation of ₹1,21,243 crore at the 29 October 2026 close (₹2,244.00 a share), a PE ratio of 90.5 on the last four quarters' profit and a price-to-book ratio of 20.01. In FY26 its consolidated net profit attributable to shareholders was ₹889 crore on revenue of ₹6,813 crore; in Q2 FY27 (July–September 2026) it was ₹441 crore, up 126.4% year on year. Its debt-to-equity ratio was 0.40 on 30 September 2026. Promoters held 27.47% of the shares on 30 September 2026.

Laurus Labs Q2 FY27 results
filed 29 October 2026
Share price used
₹2,244.00 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Laurus Labs at a glance · consolidated

Market cap
₹1,21,243 Crat ₹2,244.00 · 29 Oct close
PE ratio (last 4 quarters)
90.5136.4 on FY26 profit
Price to book (PB)
20.01book value ₹112.17 a share
ROE (FY26)
18.2%+9.8 pts vs FY25ROCE 20.5%
Debt to equity
0.40net debt ₹2,461 Cr
Promoter holding
27.47%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.09%₹2 a share in 12 months
Net worth
₹6,061 Cr+26.1% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
₹554 Cr

Questions

What is the Laurus Labs PE ratio today?

Laurus Labs' PE ratio is 90.5 at the 29 October 2026 close (₹2,244.00 a share): a market capitalisation of ₹1,21,243 crore divided by consolidated net profit attributable to shareholders of ₹1,340 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit attributable to shareholders (₹889 crore) it is 136.4.

What is the Laurus Labs PB ratio (price to book value)?

Laurus Labs' price-to-book (PB) ratio is 20.01 at the 29 October 2026 close: a market capitalisation of ₹1,21,243 crore divided by shareholders' equity (book value) of ₹6,061 crore on 30 September 2026. That is a book value of ₹112.17 per share against a share price of ₹2,244.00.

What is the Laurus Labs net worth?

Laurus Labs' net worth — shareholders' equity in its consolidated balance sheet — was ₹6,061 crore on 30 September 2026, up 26.1% from ₹4,805 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,21,243 crore at the 29 October 2026 close.

What is the Laurus Labs market cap?

Laurus Labs' market capitalisation was ₹1,21,243 crore (₹1.21 lakh crore) at the 29 October 2026 close: 54.03 crore shares at ₹2,244.00 each.

What is the Laurus Labs EPS?

Laurus Labs' basic earnings per share (EPS) were ₹16.47 in FY26, against ₹6.65 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹24.82.

What is the Laurus Labs dividend in 2026 and its record date?

In 2026, Laurus Labs has declared one dividend: ₹1.20 (interim) with record date 8 May 2026.

Is Laurus Labs debt free?

No. Laurus Labs had borrowings of ₹2,490 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.40. Its cash and current investments were ₹28.7 crore, so its net debt was ₹2,461 crore.

What is the Laurus Labs debt to equity ratio?

Laurus Labs' debt-to-equity ratio was 0.40 on 30 September 2026: borrowings of ₹2,490 crore against total equity of ₹6,181 crore. A year earlier, on 30 September 2025, it was 0.44.

What is the Laurus Labs promoter holding?

Promoters held 27.47% of Laurus Labs on 30 September 2026, unchanged from the previous quarter and down 0.12 percentage points from 27.59% a year earlier, according to the shareholding pattern filed with NSE.

What is the Laurus Labs ROE and ROCE?

In FY26, Laurus Labs' return on equity (ROE) was 18.2% and its return on capital employed (ROCE) was 20.5%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 8.4% and ROCE 11.3%.

What is the Laurus Labs shareholding pattern?

On 30 September 2026, Laurus Labs' shares were held by promoters 27.47%, foreign portfolio investors (FII/FPI) 30.84%, domestic institutions (DII) 11.86% (including mutual funds at 8.26%) and retail and other non-institutional investors 29.83%. Over the year, FII holding was up 4.68 percentage points from 26.16% and DII holding was up 0.13 percentage points from 11.73%.

What are the Laurus Labs latest quarterly results?

Laurus Labs' latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net profit attributable to shareholders ₹441 crore, up 126.4% from ₹195 crore in Q2 FY26; revenue from operations ₹2,206 crore, up 33.4% year on year.

What is the Laurus Labs book value per share?

Laurus Labs' book value per share was ₹112.17 on 30 September 2026: shareholders' equity of ₹6,061 crore divided by the 54.03 crore shares in issue, up 26.0% from ₹89.02 a year earlier. The share price at the 29 October 2026 close was ₹2,244.00.

What is the Laurus Labs dividend yield?

Laurus Labs' dividend yield is 0.09% at the 29 October 2026 close: dividends of ₹2 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹2,244.00. They were ₹1.20 on 8 May 2026 (interim) and ₹0.80 on 31 October 2025 (interim).

What is the Laurus Labs free cash flow?

In FY26, Laurus Labs generated ₹1,624 crore of cash from operations and spent ₹1,070 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹554 crore. In FY25 it was −₹39.4 crore.

What is the Laurus Labs revenue and profit in FY26?

In FY26 (April 2025–March 2026), Laurus Labs' consolidated net profit attributable to shareholders was ₹889 crore, up 148.0% from ₹358 crore in FY25, on revenue from operations of ₹6,813 crore (up 22.7%). Over three years, from FY23, net profit was up 12.5%.

When are the Laurus Labs next results?

Laurus Labs has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

How does the Laurus Labs PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Laurus Labs' PE ratio is 136.4, the highest of the four: Divi's Labs 99.7, Gland Pharma 49.4 and Mankind Pharma 53.3, a peer average of 67.5. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Laurus Labs compare with its peers?

On FY26 consolidated figures, against Divi's Labs, Gland Pharma and Mankind Pharma: Laurus Labs' operating margin of 19.1% is the third highest of the four (Divi's Labs 28.2%, Gland Pharma 18.8%, Mankind Pharma 19.1%; peer average 22.0%); its return on equity of 18.2% is the highest of the four (Divi's Labs 16.2%, Gland Pharma 10.5%, Mankind Pharma 12.5%; peer average 13.1%); its revenue growth over three years of 4.1% a year is the lowest of the four (Divi's Labs 10.8% a year, Gland Pharma 21.1% a year, Mankind Pharma 17.7% a year; peer average 16.5% a year).

Laurus Labs vs Divi's Labs: how do they compare?

In FY26, Laurus Labs earned net profit attributable to shareholders of ₹889 crore on revenue of ₹6,813 crore, against ₹2,568 crore on ₹10,560 crore for Divi's Labs. Laurus Labs' operating margin was 19.1% (Divi's Labs 28.2%) and its return on equity 18.2% (Divi's Labs 16.2%). At the 29 October 2026 close, Laurus Labs' market capitalisation was ₹1,21,243 crore against ₹2,56,096 crore for Divi's Labs, and its PE ratio on FY26 profit 136.4 against 99.7.

Where do these Laurus Labs figures come from?

From Laurus Labs' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.